AZ Sint-Jan Brugge-Oostende AV

LINKÖPING, Sweden, July 3, 2024 /PRNewswire/ -- Two hospitals in Belgium are successfully live with the public cloud service from international medical imaging IT and cybersecurity company Sectra (STOCKHOLM: SECT-B) . As the first to use Sectra One Cloud in the Benelux countries, the two hospitals have begun experiencing the benefits of a cloud service such as improved ability to share resources between the sites and more streamlined workflows. In the city of Bruges in Belgium, the hospitals AZ Sint Lucas and AZ Sint Jan began their journey to the cloud following a contract with Sectra signed in 2023. As the first in the Benelux countries to adopt Sectra's enterprise imaging as a fully managed service in the public cloud, these hospitals have now gone live with the service. One of the main reasons for this shift was the need to streamline operations and enhance collaboration between the two sites. Since 2021, the 23 radiologists and nine trainees of both hospitals have worked together in one single association. Previously, they were unable to work in one environment as they were using two different PACS providers. This made it much harder to collaborate. This need originates from the challenge many hospitals face today of dealing with heavy workloads. "With an aging population come increasing needs. We are already experiencing a lack of resources and heavier workload. With more and more exams to report on and a shortage of staff, our radiologists are having a hard time coping with the everyday workload. A state-of-the art communal PACS system could help streamline workflow and improve efficiency," says Dr. Jesse Marrannes, radiologist at AZ Sint-Jan and main medical responsible for this PACS project. Bart Thielen, Managing Director, Sectra Benelux, adds: "Healthcare today needs to be able to cope with the increasing need for diagnostics and specialized care. Transitioning to the cloud is the first step for hospitals wanting to use new technology to cope with these challenges, as the service offers the needed scalability and security. Many hospitals also deal with staff shortages when it comes to qualified IT staff. I am very happy to offer a solution that will take away some of the stress and resources usually needed to manage the system." He continues: "AZ Sint Jan and AZ Sint Lucas pave the way for the transition to public cloud for medical imaging in the Benelux and I'm excited to follow their journey." The service is based on Microsoft Azure and fully managed by Sectra. The hospitals saw the potential of the service helping to relieve burden on their IT staff and resources. "The fact that it is a fully managed service and deployed in the cloud gives us more time to focus on the care of our patients rather than on the maintenance of the IT-system and the storage and accessibility of data," said Annelies Meyns, Head of ICT Applications at AZ Sint Jan, when the project was initiated. The implementation process began shortly after the contract was signed, with Sectra closely collaborating with hospital teams to ensure a seamless transition. "Moving everything to the cloud is a monumental task, but Sectra's commitment made it manageable and efficient," says Jurryt Laleeuwe, Head of ICT Applications at AZ Sint Lucas. The cloud service is now fully operational, bringing notable enhancements. "The new system has already enhanced our ability to share resources and collaborate on patient cases. The ability to tailor our workflows has also greatly benefited our radiologists, especially for overarching multidisciplinary team meetings" says Dr. Pieter Vandaele, Head of the Department of Radiology at AZ Sint Lucas. He continues: "The implementation and experience so far have been very positive, and I look forward to seeing the ongoing benefits of this cloud service." Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra's website to read more about Sectra and why it's top-ranked in "Best in KLAS." About Sectra Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2023/2024 fiscal year totaled SEK 2,964 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra's website. For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27 Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10 This information was brought to you by Cision The following files are available for download:

Oral presentation will highlight new data in Early Access Program (EAP) for patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. This is the seventh year that MaaT Pharma's abstracts have been chosen for presentation at the EBMT Annual Meeting, confirming the Company’s leadership in the field of hemato-oncology/ microbiome. LYON, France--(BUSINESS WIRE)-- Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients. The data will be shared during an oral presentation at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation held in Glasgow, UK, from April 14-17, 2024. Details from the presentation will be disclosed in a press release on April 17th, 2024, in compliance with the conference embargo policy. Aligned with its mission to enhance the survival of cancer patients, MaaT Pharma has been actively involved in the EAP in Europe since 2019. The Company has consistently presented real-world data from its EAP at major hematology conferences over the past four years. At each data communication point, EAP results confirm previous findings, that MaaT013 has an impact on overall survival (OS) when the primary endpoint (gastrointestinal Overall Response Rate at D28) is achieved (see press release on data presented at 2023 ASH[1] annual meeting). To date, over 220 patients have been treated with MaaT013 in Europe in clinical trials and the EAP. In the context of the EAP, the Company has bolstered its manufacturing & supply chain, ensuring timely and safe provision of MaaT013 to 38 stem cell transplant hospitals across 6 European countries: Austria, Belgium, France, Germany, Italy, and Spain. Dr. Michael Loschi, hematologist at Nice Hospital in France emphasized “we are enrolling in the EAP due to the lack of third-line treatment options for patients with aGvHD who are unresponsive to corticosteroids and ruxolitinib. We receive MaaT013 within 48 hours following the request via a simple procedure for EAP. This has transformed our routine to treating patients with aGvHD and significantly improved their quality of life. The data presented at ASH align with our observations in clinical practice. We've observed superior efficacy with more complete responses[2] in gastrointestinal aGvHD and less toxicity when compared to other immune suppressive drugs." “I find the procedure in EAP to be quite straightforward” shared Dr. Alexander Schauwvlieghe, hematologist at AZ Sint-Jan Brugge AV Hospital in Belgium. “I'm a strong advocate for gut microbiome-based treatments, such as MaaT013, that prioritize immune restoration in GvHD. This approach helps maintain the patient's immune function, reducing the risk of infectious complications and relapse.” A pivotal Phase 3 trial (n=75) evaluating MaaT013 (ARES trial - NCT04769895) in patients with corticosteroid and ruxolitinib-refractory gastrointestinal aGvHD is currently ongoing to confirm the results from the EAP. The Company previously shared the positive review by DSMB[3] for the Phase 3 ARES trial, including a favorable benefit/risk ratio, with “high efficacy and low toxicity.” Details of Oral Presentation at EBMT 2024 Title: Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe Abstract number: OS13-07 Session: OS13 Oral Session 13 | GVHD Session Date/Time: Wednesday, April 17, 10:30 – 11:45 Location: Hall 5 About MaaT Pharma MaaT Pharma, a leading clinical-stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma initiated an open-label, single-arm Phase 3 clinical trial in patients with acute GvHD, building on the positive results of its Phase 2 proof-of-concept. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT). Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. [1] American Society of Hematology [2] No evidence of aGvHD [3] Data Safety Monitoring Board View source version on businesswire.com: Contacts MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 media@maat-pharma.com Trophic Communications – Corporate Communications Jacob VERGHESE or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu Source: MaaT Pharma View this news release online at:

The system enables doctors performing an ablation to toggle between two types of energy: pulsed-field and radiofrequency. It appears to be the Johnson & Johnson MedTech subsidiary’s answer to the dual energy ablation tech coming out of Affera, which competitor Medtronic acquired for $1 billion last year. Dr. Tom De Potter performed the first procedure with Thermocool SmartTouch at OLV Hospital in Aalst, Belgium. Biosense Webster said Dr. Mattias Duytschaever of AZ Sint-Jan Brugge Oostende AV performed several additional cases. The Brugge, Belgium, hospital is also taking part in the clinical trial. “While radiofrequency ablation has decades of safety and efficacy data to support it, pulse field ablation is a novel technology that shows promise in advancing the safety and ease of catheter ablation procedures; the versatility of a dual-energy catheter would give electrophysiologists the choice of using either one or both modalities at their fingertips,” said De Potter. “In caring for patients with AFib, my goal is to deliver a treatment that is maximally safe and efficient at the same time, and this dual-energy system may give me the ability to switch between radiofrequency and pulsed-field and customize treatment during a procedure to deliver the most appropriate energy.’’ Biosense Webster designed Thermocool SmartTouch SF for dual energy pulsed-field/radiofrequency ablation. It’s evaluating the PF/RF ablation system as part of the SmartfIRE study. SmartfIRE evaluates the system for treating drug-refractory, symptomatic paroxysmal AFib during standard electrophysiology mapping and ablation procedures. About the Biosense Webster ablation procedure To treat disorders like AFib, pulsed-field ablation utilizes a controlled electric field to selectively ablate cardiac tissue causing irregular heartbeats. This occurs through a process called irreversible electroporation (IRE). Its potential advantages versus radiofrequency ablation or cryoablation include the characteristic that heart muscle tissue can be especially susceptible to it. Meanwhile, other types of surrounding tissue are injury resistant. about pulsed-field ablation here. Biosense Webster aims to evaluate its Thermocool SmartTouch catheter and TruPulse generator. The steerable, multi-electrode, luminal, irrigated catheter holds CE mark for use in catheter-based cardiac electrophysiology mapping. It also has European approval for cardiac ablation when used with an RF generator. TruPulse provides both RF energy and novel, uni-polar, bi-phasic pulse sequence to the catheter by toggling the two energy sources on the generator monitor. The combination of Thermocool SmartTouch and TruPulse is not available for sale in any region. Biosense Webster’s study is investigating the combination’s transmission of PF or RF energy to the catheter tip electrode for ablation. Both integrate with the Carto 3 system. Data from this study could add to a growing body of evidence from Biosense Webster in support of PF ablation for AFib. The company last month reported early success in a clinical trial for its VariPulse catheter and TruPulse generator. Pulsed-field ablation continues to garner interest Medtronic announced yesterday that its PulseSelect pulsed-field ablation (PFA) system exceeded its safety performance goal in a clinical trial. Alongside studies from Biosense Webster and from Boston Scientific for its Farapulse ablation technology, the space continues to excite. Analysts noted that Medtronic’s study featured more rigorous AFib monitoring and endpoints compared to studies evaluating the Boston Scientific Farapulse and the Biosense Webster VariPulse systems. BTIG analyst Marie Thibault also pointed to other PFA devices in Medtronic’s portfolio. That includes the Sphere-9 PFA system from Affera. “We remain bullish on PFA as a technology class and note there are several other public and private players developing competing approaches,” Thibault said. Celine Martin, Johnson & Johnson group chair, cardiovascular & specialty solutions (CSS) group, oversees Biosense Webster’s AFib work. At DeviceTalks West in October 2022, she described pulsed-field ablation as a new chapter in the “ablation book.” Biosense Webster’s dedication in the AFib treatment space has made it a major provider of RF ablation tech. Now, Martin said, the goal is to “provide clinicians with the same portfolio that exists today in radiofrequency and make it PF-enabled.” Martin echoed the same sentiments in today’s news release: “As a long-standing leader in the field of cardiac ablation, we are working to bring forward a versatile, best-in-class portfolio of pulsed-field ablation solutions – complementary to our radiofrequency ablation catheter portfolio – to address various ablation strategies in the treatment of atrial arrhythmias.”